Friday, May 3, 2024, San Antonio, Texas, 8:00 AM – 10:00 AM Central Time (9:00 AM – 11:00 AM Eastern Time)
Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Prostate Cancer
A CME Satellite Symposium Held in Conjunction with the American Urological Association Annual Meeting 2024 (AUA2024)
Event Details
Henry B González Convention Center
900 E Market Street
San Antonio, Texas
Phone: (210) 207-8500
Program Schedule — Central Time
7:30 AM – 8:00 AM — Registration and Breakfast
8:00 AM – 10:00 AM — Educational Meeting
Meeting Room
Hemisfair Ballroom — C2 (Ballroom Level)
This event will also be webcast live.
Please see Registration tab for details.
Rahul Aggarwal, MD
Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research
Director, Genitourinary Medical Oncology
University of California, San Francisco
Department of Medicine
Division of Hematology/Oncology
Associate Director for Clinical Research
UCSF Helen Diller Family
Comprehensive Cancer Center
San Francisco, California
Adam S Kibel, MD
Chair, Department of Urology
DiNovi Family Distinguished Chair in Urology
Brigham and Women’s Hospital
Elliott Carr Cutler Professor of Surgery
Harvard Medical School
Boston, Massachusetts
Laurence Klotz, CM, MD
Professor of Surgery, University of Toronto
Sunnybrook Chair of Prostate Cancer Research
Chair, Council for Academic Freedom at University of Toronto (CAFUT)
Member, Order of Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Sandy Srinivas, MD
Professor of Oncology
Clinical Research Leader, GU Oncology
Stanford University
Stanford, California
Moderator
Elisabeth I Heath, MD
Associate Center Director, Translational Sciences
Chair, Genitourinary Oncology
Multidisciplinary Team
Professor of Oncology and Medicine
Hartmann Endowed Chair
for Prostate Cancer Research
Director, Prostate Cancer Research
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.
Agenda
7:30 AM – 8:00 AM — Registration and Breakfast
8:00 AM – 10:00 AM — Educational Meeting
MODULE 1: Recent Data Defining the Optimal Use of Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Kibel
- Rationale for the evaluation of treatment intensification with secondary hormonal agents combined with androgen deprivation therapy (ADT) for nonmetastatic prostate cancer
- Design of, eligibility criteria for and major efficacy and safety findings from the Phase III EMBARK trial evaluating enzalutamide with leuprolide versus enzalutamide or leuprolide alone for patients with nonmetastatic hormone-sensitive prostate cancer (nmHSPC) and high-risk biochemical recurrence after definitive therapy
- Published data from the Phase III PRESTO trial evaluating ADT intensification with apalutamide with or without abiraterone for patients with high-risk biochemically relapsed prostate cancer; potential role of this strategy
- Ongoing Phase III trials investigating secondary hormonal agents alone or in combination with ADT for patients with nmHSPC
- Long-term findings documenting the effectiveness of enzalutamide, apalutamide and darolutamide for patients with nonmetastatic castration-resistant prostate cancer
MODULE 2: Side Effects and Other Practical Considerations with Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Klotz
- Tolerability profile of enzalutamide with and without ADT in the EMBARK study; differences, if any, from the experience with this agent in later disease settings
- Incidence of hypertension and other cardiovascular adverse events (AEs) with different hormonal agents; optimal pretreatment cardiovascular assessment and monitoring/management of side effects during therapy
- Spectrum and frequency of CNS-related AEs (eg, seizure, cognitive decline, falls, fatigue) observed with hormonal therapy in patients with prostate cancer
- Risk of pathologic and nonpathologic fractures with ADT and androgen receptor (AR) pathway inhibitors; guideline-recommended bone health assessments for patients receiving hormonal therapy for prostate cancer
- Prevalence of other notable side effects with available hormonal therapies for prostate cancer
MODULE 3: Current and Future Approaches to Hormonal Therapy for Metastatic Prostate Cancer — Dr Aggarwal
- Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with metastatic HSPC (mHSPC); appropriate integration of these therapies into practice
- Published efficacy and safety data from the Phase III ARASENS trial evaluating darolutamide in combination with docetaxel and ADT for mHSPC
- FDA approval of darolutamide/docetaxel/ADT for mHSPC; selection of optimal candidates for triplet therapy
- Biological rationale for targeting the PI3K-AKT-mTOR pathway in prostate cancer; mechanism of action of and early data with capivasertib
- Design, eligibility criteria and key endpoints of the Phase III CAPItello-281 study evaluating capivasertib in combination with ADT/abiraterone for mHSPC and PTEN deficiency
- Other ongoing research investigating capivasertib for metastatic prostate cancer, such as the CAPItello-280 trial
MODULE 4: New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Srinivas
- Incidence of BRCA1/2 and other homologous recombination repair (HRR) abnormalities in patients with prostate cancer; indications for and practical implementation of genetic testing
- Similarities and differences in the designs and eligibility criteria of the Phase III PROpel, MAGNITUDE and TALAPRO-2 trials combining olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide, respectively, in the first-line setting for mCRPC
- Key efficacy and safety findings from PROpel, MAGNITUDE and TALAPRO-2 in patients with and without BRCA and other HRR gene mutations
- FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide in mCRPC; individualized selection among these approaches
- Long-term data with and current clinical role of olaparib and rucaparib monotherapy for patients with mCRPC
- Ongoing Phase III studies evaluating PARP inhibitors in combination with secondary hormonal therapy in earlier disease settings
MODULE 5: Other Novel Therapies for Patients with Metastatic Prostate Cancer — Dr Heath
- Available data with, patient selection for and ongoing assessment of radium-223 in prostate cancer
- Published Phase III data sets (eg, from the VISION and PSMAfore trials) with lutetium Lu 177 vipivotidetetraxetan for patients with PSMA-positive mCRPC; appropriate sequencing of lutetium Lu 177 vipivotide tetraxetan
- Ongoing Phase III PSMAddition trial evaluating lutetium Lu 177 vipivotide tetraxetan in combination with AR-directed therapy and ADT for patients with mHSPC
- Emerging positive findings from the Phase III SPLASH trial evaluating the investigational PSMA-targeted radiopharmaceutical 177Lu-PNT2002 for patients with mCRPC who have experienced disease progression on an AR pathway inhibitor and refuse or are not eligible for chemotherapy; potential implications for practice
- Key findings from the Phase III CONTACT-02 trial comparing cabozantinib/atezolizumab to a second novel hormonal therapy for patients with mCRPC and measurable soft tissue disease who have previously received a novel hormonal agent
- Other promising agents and strategies under investigation for metastatic prostate cancer
CE Information
Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.
Learning Objectives
At the conclusion of this activity, participants should be able to
- Appraise published research findings on optimal disease management approaches for patients with biochemical recurrence after local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of systemic therapy.
- Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options.
- Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into clinical management algorithms.
- Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biological factors.
- Assess the available research database supporting the use of PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with mCRPC harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
- Appreciate available Phase III data documenting the efficacy of PSMA-targeted radioligand therapy for patients with PSMA-positive mCRPC, and consider the current and future clinical role of this strategy.
- Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.
CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Aggarwal and Dr Klotz have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Kibel — Advisory Committees: Janssen Biotech Inc, Pfizer Inc, ProFound Therapeutics, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb, Candel Therapeutics. Dr Srinivas — Advisory Committees: Aveo Pharmaceuticals, Eisai Inc, Janssen Biotech Inc, Novartis, Seagen Inc; Contracted Research: Bristol Myers Squibb, Merck, Novartis, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Pfizer Inc.
CONSULTING CLINICAL INVESTIGATORS — The following consulting clinical investigators reported relevant financial relationships with ineligible entities: Jason Hafron, MD — Advisory Committees: Astellas, Dendreon Pharmaceuticals Inc, Immunis.AI, Janssen Biotech Inc, Lipella Pharmaceuticals Inc (study/trial), Pfizer Inc; Consulting Agreements: Lilly, Lynx Dx, Myovant Sciences, Myriad Genetic Laboratories Inc, Photocure, Promaxo, Tolmar; Contracted Research: Astellas, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Lipella Pharmaceuticals Inc, miR Scientific, Myovant Sciences, Myriad Genetic Laboratories Inc, Nucleix, Pfizer Inc; Patent without Royalty: Lipella Pharmaceuticals Inc; Speakers Bureaus: Amgen Inc, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Lantheus, Merck, Myriad Genetic Laboratories Inc, Pfizer Inc, PROCEPT BioRobotics, Tolmar. David S Morris, MD — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Pfizer Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Clovis Oncology, Janssen Biotech Inc, Merck, Pfizer Inc.
MODERATOR — Dr Heath — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Sanofi; Contracted Research: Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Five Prime Therapeutics Inc, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeosTherapeutics, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Modra Pharmaceuticals, MSD, Novartis, Oncolys BioPharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Seagen Inc; Honoraria/Paid Travel: Astellas, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Sanofi, Seagen Inc; Speakers Bureau: Sanofi; Nonrelevant Financial Relationship: Calibr.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.
Location
Hilton Chicago
Henry B González Convention Center
900 E Market Street
San Antonio, TX 78205
Phone: (210) 207-8500
Meeting Room
Hemisfair Ballroom — C2 (Ballroom Level)
Directions
The Henry B González Convention Center is the main venue for the AUA Annual Meeting 2024.
Registration
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.
NOTICE:
Registration for this event is independent of registration for AUA2024.
Please note, onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com.
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.